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Background
The purpose of this review is to characterize the type
of patient who may benefit from alternate, nonsteroidal
agents and to examine the current evidence behind their
use.
Methods
Evaluated the use of oral or IM low-dose methotrexate vs
placebo in steroid-dependent asthma patients using either
parallel or crossover design. 100 patients enrolled in study
attending the ent and allergy centre (India)panchkula
patients were on long term steroid therapy for more than
1 years. Age of patients between 30 to 50 years. Study
comparing methotrexate, 10 mg weekly orally, or placebo.
Results
It was concluded that methotrexate allowed a good
amount of reduction in oral corticosteroid compared to
patients receiving placebo. The benefit of using metho-
trextate were very promising as compared to side effects
of corticosteroids in steroid depoendent allergy diseases
however, and should be balanced against the potential for
side-effects associated with the use of methotrexate.
Conclusions
With low dose weekly therapy of metotrextate we can
reduce the side effects of prolonged steroids have sug-
gested that methotrextate may have steroid-sparing bene-
fits coupled to generally mild adverse events; although
adverse effects were not of a serious nature they were
observed in up to one-third of patients. Rare but
potentially life-threatening adverse effects involving the
pulmonary, hepatic and haematological systems remain
of particular concern. methotrextate should therefore be
considered as an adjunct to high dose inhaled STEROIDS
in patients who require more than 10mg of predeniso-
lone daily, and who experience severe and unacceptable
steroid-related adverse effects. Treatment should only be
initiated by physicians with experience in the use of the
drug, and the relevant safety parameters should be closely
monitored.
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